Vertex Pharmaceuticals price target raised to $437 from $425 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals to $437 from $425 and keeps a Sector Perform rating on the shares. The firm contends that suzetrigine is more likely than not to show a treatment effect in the upcoming phase 2 lumbosacral radiculopathy readout but also warns that the likely modest effect size may raise some concerns over phase 3 replicability risk, breadth of commercial use, and real-world patient persistence, which may cap upside, the analyst tells investors in a research note.